CDMOs Vetter and Rentschler Biopharma are collaborating to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain.
With drug development growing increasingly complex and cost-intensive, biopharmaceutical companies are under significant pressure to streamline their products’ path to market.
The desired goal of the collaboration is to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.
The alliance will leverage Rentschler Biopharma’s extensive experience in drug substance manufacturing, including bioprocess development and API1 production, and Vetter’s strong expertise in aseptic fill and finish and secondary packaging.
The companies have already identified opportunities, where early and active exchange of know-how and best-practice will benefit both clients and their drug products.
Over the next months, these opportunities will be further validated in pilot client projects with joint teams from both companies.
“There are important synergies between our business portfolios that will provide valuable market foresight that can positively impact our clients’ business and patients’ treatment,” said Peter Soelkner, Managing Director of Vetter.
“Combining our experience enables us to deliver new efficiencies and pathways that streamline the development and the supply chain in ways that address the challenges of complexity companies across the industry are facing.”
Both companies will continue to independently address and service current and new clients as they explore opportunities for cooperative integration of approaches to complex molecules in todays’ rapidly evolving global healthcare environment.